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Abstract
Background: Medical treatment in patient-centred care in oncology is broadly managed and regulated in terms of
guideline development, cancer centres, and quality assurance by cancer registries. In contrast to this quality management
cycle (PDCA), there are no equal standards for patient-reported outcomes like quality of life (QoL). Therefore, the Tumour
Centre Regensburg e.V., a population-based regional cancer registry covering a population of more than 2.2
million people in the Upper Palatinate and Lower Bavaria, Germany, designed and implemented a QoL pathway.
In a complex intervention with QoL diagnosis and therapy (multidimensional therapeutic network), effectiveness
for patients with breast cancer has been demonstrated. To provide local tailored QoL diagnosis and therapy to
other cancer patients as well, external validity needs to be extended by adapting the QoL pathway to another
tumour entity.
Methods/Design: The QoL pathway will be tested for colorectal cancer patients in a pragmatic randomised controlled
trial. Two hundred twenty primary colorectal cancer patients, surgically treated in one of four hospitals, will be included.
QoL is measured in all patients 0, 3, 6, 12, and 18 months after surgery (European Organisation for Research and
Treatment of Cancer (EORTC) QLQ-C30, QLQ-CR29). In the intervention group, QoL scores are transformed into a
QoL profile. This is sent to the coordinating practitioner (general practitioner, internist, or oncologist) with an expert report
including treatment recommendations for QoL deficits. The control group receives routine follow-up care attending the
guideline recommendations for colorectal cancer without profile or expert report. At the primary endpoint (12 months),
the rates of patients with diseased QoL in both groups are compared.
Discussion: This randomised trial is the first complex intervention investigating the effectiveness of an intervention with
QoL diagnosis and tailored QoL therapy in colorectal cancer patients. The results will show if this QoL pathway improves
the patients’ QoL during follow-up care of their disease.
Trial registration: ClinicalTrials.gov, NCT02321813 (registered December 2014).
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Background
There is a growing interest in using quality of life (QoL)
data not only as a relevant endpoint in clinical trials on
cancer patients, but also in routine practice in order to
improve patients’ health during treatment [1–4].
Until now, several essentials for managing ‘diseased
QoL’ have been missing. First of all, there is a need of
guidance about how to define and use diseased QoL as an
integral part of cancer treatment, for example, in patients
with good prognostic stage (UICC 0 and I) but persistently
low QoL in several dimensions requiring the doctor’s help
[5]. Furthermore, therapies rarely have been implemented
specifically to improve patients’ QoL. Additionally, there
needs to be confidence in the evidenced-based value of
such QoL therapies [6].
To achieve these aims, we designed, implemented, and
evaluated an integrated QoL diagnosis and therapy path-
way (QoL pathway) for breast cancer patients, guided by
the UK Medical Research Council framework for develop-
ing and testing complex interventions [7]. In a previous
randomised controlled trial it could be demonstrated in a
routine setting that breast cancer patients show a benefit
from tailored QoL diagnosis and therapy, having signifi-
cantly better QoL 6 months after surgery compared to a
control group treated with routine follow-up care [6].
In order to extend the external validity of our approach
it is necessary to apply its principles to another tumour
entity. Colorectal cancer was chosen for the following rea-
sons: It is the second most common form of cancer in the
Western world (69,000 new diagnosed patients/year in
Germany), responsible for about 27,000 cases of death per
year in Germany [8]. The demands of this cancer form on
QoL diagnosis and therapy differ in some important
aspects from those in breast cancer (for example, more
important part of surgical procedure because of the more
extended severe tumour extirpation and patients of both
sexes, with higher age and more comorbidities).
Many studies have demonstrated that various compo-
nents of the QoL of colorectal cancer patients are consid-
erably impaired. QoL deficits are most dominant during
the first months after surgery with some discomfort per-
sisting for a longer time, for example, impaired body
image or sexual problems [9]. One year after diagnosis,
colorectal cancer patients still suffer fatigue and reduced
emotional functioning compared to the general popula-
tion [10]. Special aspects concerning this form of cancer
are stoma-related complications. The presence of a stoma
is associated with more psychological distress and reduced
sexual functioning [11] while stoma reversal leads to a sig-
nificant improvement in physical and social functioning
and overall QoL [12]. Furthermore, it was shown that
baseline QoL is a significant prognostic indicator for sur-
vival in advanced colorectal cancer, with better QoL being
associated with a higher 1-year survival rate [13].
There is general agreement that QoL needs to be not
only considered as an endpoint in clinical trials but also in
routine health care of cancer patients. The mainstream of
research has focused on developing a routine measure-
ment of QoL in clinical practice and providing the results
to clinicians in order to improve patient-physician com-
munication [1, 2, 14, 15]. These studies, however, provide
no clues how to deal with this information because spe-
cific implications for the treatment of QoL deficits never
have been spelled out.
Therefore, we developed a QoL pathway, which con-
nects a systematic QoL diagnosis with targeted treatment
of QoL deficits in breast cancer patients. Because of the
complexity of the healthcare system, the study was con-
ducted as a complex intervention [7, 16] with theory
building [17, 18], modelling [5], exploratory trial [19], and
a definitive randomised controlled trial [6]. In the present
randomised trial, effectiveness of the QoL pathway, modi-
fied for colorectal cancer patients, is to be tested.
Objectives and hypothesis
The primary objective of the study is to improve QoL of
colorectal cancer patients during follow-up care with sys-
tematic QoL diagnosis and targeted treatment. To achieve
this aim, the following key issues are addressed:
1. Testing effectiveness of the QoL pathway with
systematic diagnosis and targeted therapy of QoL in
colorectal cancer patients during follow-up care.
2. Implementing the QoL system into routine medical
care using a multifaceted strategy including
educational outreach visits, local opinion leaders,
and continuous medical education (CME) (in
defined and modelled quality circles [5]).
3. Extension of regional network structures for QoL
therapies by creating new quality circles and by
expanding the already existing quality circles.
4. Extension of external validity by applying the QoL
pathway in another tumour entity.
5. Replication of the findings as an essential part of
complex interventions.
The following hypothesis will be investigated:
Colorectal cancer patients who receive systematic QoL
diagnosis and targeted QoL therapy (intervention) have a
significantly better QoL in the first postoperative year
compared to patients who receive routine follow-up care
(control).
Methods/Design
The study is a two-armed, randomised, controlled, pro-
spective, single-blind, pragmatic, clinical trial with an inter-
vention group and a control group.
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Participants and recruitment
Four hospitals with certified colorectal cancer centres in
Bavaria, Germany, accredited by the German Cancer Soci-
ety (DKG), take part in patient recruitment: Krankenhaus
Barmherzige Brüder, Department of Surgery, Regensburg;
Caritas-Krankenhaus St. Josef, Department of Surgery,
Regensburg; Klinikum Neumarkt, Department of Surgery,
Neumarkt; Klinikum St. Elisabeth Straubing, Department
of Surgery, Straubing. Before the beginning of the trial the
number of patients fulfilling the inclusion criteria has been
collected in the four hospitals for the year 2011 in order
to see if enough eligible patients are available. There has
been a pilot phase in the hospitals for the QoL pathway in
order to implement patient recruitment and postsurgical
QoL measurement into clinical routine. To achieve an
adequate participant enrolment there is regular contact
between the QoL Unit and the surgeons recruiting
patients in the four hospitals. Moreover, the participating
clinics are certified cancer centres that need enrolment of
patients into studies for the certification process and thus
should be highly motivated to include patients in the trial.
Patients are included under broad inclusion criteria:
(1) diagnosis of primary colorectal cancer and (2) sur-
gery in one of the four participating hospitals. Exclusion
criteria are as follows: (1) recruiting surgeon (QoL clinician)
is not available (illness, holiday, other reasons); (2) patient is
misclassified in the operation schedule (no primary oper-
ation or no colorectal tumour); (3) coordinating practi-
tioner (physician, caring for the patient) chosen by the
patient refuses trial participation; (4) patient is from outside
the defined study region (Bavaria, Germany: urban county
of Regensburg, rural county of Neumarkt, Straubing,
Straubing-Bogen, Kelheim, Schwandorf); (5) age under
18 years; (6) pregnancy; (7) patient unable to fill out the
QoL questionnaire for physical, psychological, or language
reasons (including dementia); or (8) patient refuses to par-
ticipate in the study. To insure high external validity [20] ,
there will be no exclusion of elderly patients or exclusion
according to tumour stage or patient sex. Furthermore, no
constraints will be made according to surgical procedure or
ASA score (American Society of Anesthesiologists); how-
ever, these factors will be accounted for in data analyses.
External validity is also kept high by population-based
inclusion of patients of urban and rural areas and by imple-
menting the QoL pathway into routine follow-up care.
Moreover, data of the cancer registry of excluded patients
and other hospitals in the study region can be analysed
according to medical and demographic data of patients to
test representativeness of our study population. The selec-
tion of study participants is shown in Fig. 1.
Coordinating practitioners (CPs) are defined as those
physicians who care for the colorectal cancer patients after
hospital stay. They are either general practitioners, or
internists, or oncologists. CPs are eligible for the project if
they give their informed consent to participate in the trial
(CP is informed by the patient’s surgeon by phone about
the study) and agree to be implemented by an educational
outreach visit. Outreach visits are performed by two
trained individuals of the QoL Unit who meet with the CP
in his practice and introduce him to the concept of QoL,
stressing the importance of considering QoL in medical
care of colorectal cancer patients and who give the CP an
overview about the procedure of the study. Outreach visits
are structured by using fixed presentation slides for the
implementation of each CP.
Fig. 1 Selection of patients
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Randomisation and blinding
Balanced randomisation [21] is used with random per-
muted blocks of 20 patients followed by a sequence of 11
blocks for 220 patients with a second, simple randomisa-
tion. Five digit random numbers from the RAND Corpor-
ation [22] are used for both steps. Based on this random
list of digits an external co-worker, otherwise not involved
in the trial, created 220 paper cards specifying the groups
and inserted them in 1 to 220 serially numbered opaque,
sealed envelopes. This stack of envelopes is kept in a locked
safe at the QoL Unit at the Tumour Centre Regensburg
and is accessible only by the two study coordinators.
Randomisation of individual patients is performed using
the following described procedure. The study clinician in
each of the four recruiting hospitals determines eligibility
of the study patient. If all criteria are fulfilled and the
patient has granted informed consent the study clinician
sends the recruitment document to the QoL Unit. The
study number 1 to 220 is determined by the exact date
and time of fax entry. The CP will be informed by the
QoL Unit about allocation of the individual patient either
to the intervention or the control group.
The CP will be obliged not to share this knowledge with
the patient. In order to control for bias, participants will be
kept blind throughout the study about their allocated group
(single blind design). At the end of the trial, the patients’
blindness about their allocated group will be checked.
At no point in the process will the recruiting clinician in
the hospital access the sealed envelopes or be informed
about the group allocation.
Procedure
Written informed consent is obtained from each participant
before they are included into the study. All participants
(intervention and control group) repeatedly fill out a QoL
questionnaire (EORTC QLQ-C30, QLQ-CR29 [23–25]) at
the following times: 0 to 2 days before discharge from
hospital and 3, 6, 12 and 18 months postoperatively. The
first QoL measurement takes place in hospital and the fur-
ther measurements (3, 6, 12, 18 months postoperatively)
are carried out in the CP’s practice during follow-up. For
each assessment time point participants receive a postal re-
minder. Guideline for colorectal cancer [26] recommends
first follow-up at 6 months. Colorectal cancer patients suf-
fer a lot of QoL deficits especially in the first months of
treatment. Therefore, we decided also to measure QoL
3 months postoperatively. Feasibility of this additional
measurement is expected to be good because most patients
visit their CP regularly. This could be also observed in the
pilot phase of the study.
Parallel to the QoL measurements, the patient’s CP pro-
vides additional information about the patient’s health sta-
tus. All data are sent to the QoL Unit at the Tumour
Centre Regensburg.
All patients are treated according to the follow-up
regimen of S3-guideline for colorectal cancer [26]. Con-
comitant care is not prohibited but will be collected and
considered in secondary data analysis.
Differences between the treatment of intervention group
and control group patients is shown in the following sec-
tion. Figure 2 gives an overview of the study flow in the
two arms of the randomised trial.
Intervention group
The QoL pathway for intervention group patients is shown
in Fig. 3. All intervention group patients receive, in addition
to routine follow-up care [26], tailored QoL diagnosis and
therapy during the first 18 months after surgery. For this
purpose measurements of a QoL questionnaire (EORTC
QLQ-C30, QLQ-CR29 [23-25]) are transformed into a
QoL profile using a computerised visualisation programme
[27]. The profile consists of scales of 0 to 100 (worst to
optimal QoL) comprising global QoL and 12 different di-
mensions considering somatic (e.g. pain), psychological (e.g.
emotional functioning), and social aspects (e.g. family life)
(Fig. 4). The QoL profile also takes into account the specific
discomfort colorectal cancer patients suffer, for example,
disability during defecation, increased bowel move-
ment, or discomfort during urination (EORTC QLQ-
CR29). A cut-off score has been constructed, which de-
fines scores < 50 points as ‘diseased QoL’.
The QoL profile and information about health status
are interpreted by a group of experts in the QoL Unit
(physicians and psychologist) who independently formulate
a QoL diagnosis and recommendations for the treatment of
diseased QoL deficits (<50 points). These are combined to
a consensus report, which will be sent with the QoL profile
(Fig. 4) to the CP caring for the patient. Four weeks after
having received the expert report, the CP will be asked by
phone by the QoL Unit, if any therapy has been performed
in response to QoL diagnosis.
Specific therapeutic options for the treatment of dis-
eased QoL have been defined (Fig. 5): pain therapy, psycho-
therapy, social support, nutrition counselling, stoma care,
physiotherapy, fitness. To provide continuous medical edu-
cation, quality circles for each therapy option are necessary.
As a result of the complex intervention in breast cancer
patients [5, 6, 19], regional network structures for QoL
therapies have been established and are available for the
current study. To meet the special needs of colorectal can-
cer patients a new quality circle for nutrition and stoma
care has been founded. CPs of intervention group patients
receive addresses of the quality circle members to contact
them easily for QoL therapy.
QoL of patients will be rechecked at 3, 6, 12, and
18 months postoperatively during follow-up in the practice
of the CP with QoL diagnosis and therapy following the
same procedure as described above.
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Control group
In the control group patients’ QoL is also assessed be-
fore clinical discharge and at 3, 6, 12, and 18 months
postoperatively during medical follow-up. In contrast to
the intervention group, the CP of a control group patient
is not informed about the results of patient’s QoL meas-
urement (neither the QoL profile nor expert report are
sent to him). Patients receive standard follow-up care
according to the S3-guideline for colorectal cancer [26]
(see Fig. 2).
Measures
Quality of life (patient)
Quality of life is measured by using the validated QoL
questionnaire of the European Organisation for Research
and Treatment of Cancer (EORTC), consisting of a core
Fig. 2 Trial profile: patients flow through each stage in two arms of the randomised controlled trial (CP, coordinating practitioner)
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module (EORTC QLQ-C30 [25, 28]) and a module for
colorectal cancer patients (EORTC QLQ-CR29 [23, 24]).
The questionnaire is a self-administration instrument with
a multidimensional structure measuring QoL on a four-
point Likert scale or rather on a seven-point Likert scale for
the global dimension QoL. Satisfying internal consistency
and good retest-reliability, as well as construct and clinical
validity, have been demonstrated [24, 28, 29].
Fig. 3 Patients in the intervention group (quality of life (QoL) pathway) following recruitment for the randomised trial. This pathway is considered
for clinical routine
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In every dimension scores are uniformly transferred to
a scale from 0 (very bad QoL) to 100 (very good QoL).
A cut-off score has been constructed, which defines
scores < 50 points as diseased QoL. This score has been
extensively discussed and accepted in the present form
by consensus of a large group of clinicians [5, 6, 18].
For outcome measurement of the present randomised
trial, 13 different scales have been selected according to
the results of the previous randomised trial in breast can-
cer patients [6], the appraisal of relevance for QoL of colo-
rectal cancer patients, and the availability of therapy
options (global QoL, physical functioning, role function-
ing, pain, discomfort during defecation, increased bowel
movement, discomfort during urination, body image,
emotion, concentration/remembering, fatigue, family life/
social encounters, and financial situation).
Fig. 4 Quality of life (QoL) profile and expert reports of a colorectal cancer patient (pilot study) with QoL diagnosis and therapy. Male, with primary colon
carcinoma, 56 years. Prognostic classification T3 N2a M1 (per) G3. Left hemicolectomy, subtotal pancreas resection, splenectomy. Adjuvant chemotherapy.
Grey bar=Cut-off for diseased/healthy QoL (50 points)
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Health status (surgeon/CP)
The first measurement of health status is performed be-
fore discharge from the hospital. The surgeon gives in-
formation about the following demographic and medical
characteristics of the patient: age, sex, marital status, chil-
dren, occupation, ASA classification, tumour stage, date of
surgery, surgical procedure, complications, comorbidities,
(neo)adjuvant therapies, other current or planned therapies
(for example, pain therapy, psychotherapy physiotherapy),
CEA, preoperative symptoms, height, and weight. The type
of surgery and ASA classification especially are expected to
affect strongly colorectal cancer patients’ QoL [30]. These
variables will be considered in data analysis, but neither
specific surgical procedures nor higher ASA classifications
will be excluded in order to achieve high external validity.
During follow-up the CP gives written information about
health status at 3, 6, 12 and 18 months postoperatively re-
garding CEA, finished, current, or planned therapies, and
complications. Additionally, the CP makes an assessment
of the patient’s global QoL on a seven-point Likert scale.
Telephonic enquiries (CP)
Four weeks after the patient has filled out the QoL ques-
tionnaire, a member of the QoL Unit calls the CP by tele-
phone and asks if anything has been done to improve the
patient’s QoL. The reason for this is that in the interven-
tion group CPs receive a QoL profile and an expert report
with recommendations for improving their patients’ QoL.
Therefore, whether anything has been done in response to
the expert report is to be recorded by phone call. In order
to ensure comparability of patients in both study arms,
there are also telephonic enquiries for CPs of control
group patients.
Patient satisfaction (patient)
After the patient has finished the last QoL measurement at
18 months postoperatively, a questionnaire will be sent to
the patient’s home. The questionnaire includes quantitative
and qualitative questions on patient satisfaction regarding
(medical) care since the diagnosis of colorectal cancer and
usefulness of the repeated QoL measurements. Addition-
ally, the blindness of patients about their allocated group is
checked.
Ethics and monitoring
This study has received full ethical approval through the
ethics committee of the University of Regensburg (internal
reference number 12-101-0014). The trial is registered with
ClinicalTrials.gov, trial registration number NCT02321813.
A central ethical question has to be answered before
conducting a randomised trial: Is a new treatment denied
to the control group from which those might benefit? In
our study, control group patients are treated according to
the S3-guideline for colorectal cancer (26) but do not
receive additional targeted QoL therapy based on system-
atic diagnosis. Nevertheless, it can be expected that control
group patients also benefit from study participation
because their CP will also be trained in assessing QoL and
therefore is expected to be sensitised for QoL deficits of
his patient. It must also be considered that the new inter-
vention or specific treatment of QoL might bear a risk for
patients in the intervention group. Furthermore, emotional
drain by filling out QoL questionnaires is conceivable. An
insurance for patients’ safety was taken out to cover any
possible harm of trial participants.
The randomised trial on breast cancer patients [6] did
not show any evidence of possible harm elicited by the
Fig. 5 Traditional and hermeneutic therapeutic options for patients with colorectal cancer. An integrated model
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QoL pathway. For monitoring patient safety, patient’s CP
is repeatedly contacted by phone about 1 month after the
patient has filled out the QoL questionnaire (telephonic
enquiries) and is asked whether he has recognised any
negative effect on the patient. Serious adverse events, in-
cluding death or admission to hospital, will be recorded,
analysed, and reported to the local ethics committee.
Primary and secondary outcomes
The first primary endpoint (1) will be the proportion of
patients in both groups with diseased QoL (<50 points in
at least one dimension) 12 months postoperatively. Twelve
months were chosen because adjuvant therapies and stoma
reversal are often not finished 6 months postoperatively.
The second primary endpoints (2), enhancing the cred-
ibility of the first primary endpoint, are the rates of patients
with diseased QoL in each dimension of the profile
12 months after surgery.
The primary endpoints formulated above will be tested
in the strict order (1), (2), that is, a statistical testing pro-
cedure with a priori ordered hypotheses is applied [31].
This binary primary endpoint was chosen for two reasons:
(1) according to our conceptual groundwork [5, 19] 50
score points on a 0 to 100 QoL scale defines healthy ver-
sus diseased QoL, and (2) the same primary endpoint was
used in our randomised trial on breast cancer patients and
generated a significant difference according to our hypoth-
esis [6].
Sample size
The trial sample size was calculated by means of the first
primary endpoint (lack of a QoL deficit in the QoL profile,
that is, all scores are ≥ 50 score points). Based on the rando-
mised controlled trial on breast cancer patients (6), we ex-
pect that 45 % of the patients in the intervention group
report no QoL deficit 12 months after therapy, but only
25 % in the control group. Setting α at 5 % and power (1-β)
at 80 %, 89 patients are needed in each group in order to
detect the hypothesised difference when calculating the
Χ2 test. To compensate for 20 % drop-outs (death or
refusal) within the 12 months observation period, we
will enrol 110 patients per group, and thus, the total
sample size will be 220.
Statistical analyses
Trial data are entered into a Microsoft ACCESS (version
2007) database, which is installed on a password-protected
computer without physical connection to the internet. All
data entered into the database are controlled by a second,
independent member of the QoL Unit.
All variables will be presented using descriptive
statistics (frequencies, percentages, means/standard
deviations, medians/interquartile ranges, and various
graphical representations). Point estimates will be ac-
companied by confidence intervals.
The design for the two primary endpoints is based on a
method of fixed a priori ordered hypotheses [31]. Thus,
the second primary endpoints will only be analysed, if the
null hypothesis of the first primary endpoint can be
rejected (P < 0.05). This design assures a global alpha of
0.05. The analyses of the primary endpoints (including
both first and second primary endpoints) will be con-
ducted using the Χ2 test (or Fisher’s exact test if the smal-
lest expected cell value is < 5), setting the level of statistical
significance at P < 0.05. It is not planned to use imputation
to handle missing data in primary analysis.
Statistical tests regarding the secondary endpoints will
also use the P < 0.05 significance threshold, but all second-
ary results will be interpreted in an exploratory manner.
Secondary analyses will start with an ANCOVA using
the continuous QoL data as dependent variable and base-
line QoL, comorbidity, sex, age and study site as covariates.
Other secondary analyses will focus on exploratory sub-
group analyses. These include the influence of different
surgical procedures on QoL and the benefit these different
subgroups gain from the QoL pathway. Furthermore, risk
factors for diseased QoL (ASA, stoma, type of tumour
(colon/rectum), age and sex) will be investigated. Tests of
significance will include the Mann-Whitney U test, Kruskal
Wallis test, t-test, and ANOVA or McNemar, depending
on the number of groups, their independence/dependence,
and the scaling of the dependent variable.
For qualitative data in the final questionnaire about
patient satisfaction, a category system will be created and
answers will be categorised by independent raters, so that
frequencies of key categories can be quantitatively ana-
lysed by using descriptive statistics [32].
A detailed statistical analysis plan (SAP) will be written
before all analyses commence.
Discussion
In a complex intervention a clinical pathway with QoL
diagnosis and QoL therapy has been developed, imple-
mented, and the effectiveness has already been demon-
strated for breast cancer patients. To provide the QoL
pathway to other cancer patients as well, external validity
needs to be extended by adapting the QoL pathway to an-
other cancer type.
This randomised trial is the first complex intervention
investigating the effectiveness of an intervention with regu-
lar measurement and treatment of QoL in colorectal can-
cer patients. The primary objective is to improve the QoL
of the patients during follow-up care by systematic diagno-
sis and tailored therapy of diseased QoL. This regular
screening of QoL combined with targeted therapy is sup-
posed to support the prevention of chronic QoL deficits
like fatigue or reduced emotional functioning.
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Therefore, the treatment of cancer patients’ QoL needs
to be just as standardised as medical therapy. This is a
major strength of this study. In contrast to other interven-
tional trials on QoL, the setting of this study is not limited
to the inpatient process but encompasses especially ambu-
lant routine follow-up care. Furthermore, the QoL pathway
exceeds other approaches to improve QoL by not only
measuring QoL and presenting results but also giving rec-
ommendations how to improve QoL, providing regional
network structures for QoL therapy. Additionally, the trial
is expected to have high external validity, for example, no
exclusion of older patients, of specific tumour stages, or of
patients with comorbidities. Therefore, the study has been
carefully designed to reflect routine attending the recom-
mendations in the S3-guideline. The four cancer centres
responsible for patient recruitment are considered to be
representative for institutions in which the QoL system is
planned to be implemented in routine health care in the
future. During the recruitment phase all colorectal cancer
patients, surgically treated in the four hospitals, will be
screened for study eligibility. We also expect a special mo-
tivation of CPs to participate in the trial because they are
informed about the study by their patient’s surgeon and
are implemented by an educational outreach visit. More-
over, thorough planning and a lot of preliminary work have
been done in the course of the complex intervention
including theory building [17, 18], modelling [5], and pilot
testing.
A limitation is the complexity of the trial. As a result,
it might be difficult to determine which specific facet of
the intervention is responsible for an effect. Therefore,
the specific QoL therapies patients receive at any time of
measurement are recorded and will be investigated for
effectiveness in subgroup analyses.
To disseminate study results, full text publications and
presentations at conferences will be realised as well as the
transfer of the results into the medical education of physi-
cians and students. Furthermore, the randomised trial is an
implementation study for colorectal cancer patients as
well. The QoL system has already been implemented for
patients with breast cancer in the area of Regensburg and
is now implemented for colorectal cancer patients. The ef-
fectiveness of this modified QoL pathway in such a differ-
ent patient population will be tested in this prospective
randomised trial. In the long term, the QoL system is
planned to be implemented for the whole region of
Germany.
Trial status
Recruitment for the trial began in January 2014 and is still
in progress.
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